0001399529-20-000090.txt : 20201106 0001399529-20-000090.hdr.sgml : 20201106 20201106175844 ACCESSION NUMBER: 0001399529-20-000090 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201104 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paglia Regina M. CENTRAL INDEX KEY: 0001813985 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 201295507 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 wf-form4_160470350893109.xml FORM 4 X0306 4 2020-11-04 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001813985 Paglia Regina M. C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Human Resources Officer Common Stock 2020-11-04 4 M 0 30000 12.93 A 30000 D Common Stock 2020-11-04 4 S 0 15000 22.25 D 15000 D Common Stock 2020-11-04 4 S 0 15000 23.25 D 0 D Employee Stock Option (Right to Buy) 12.93 2020-11-04 4 M 0 30000 0 D 2029-02-28 Common Stock 30000.0 150000 D The Reporting Person sold an aggregate of 30,000 shares of common stock on November 4, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 11.43% of 262,450 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2020. The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date. /s/ Douglas W. Pagan, attorney-in-fact 2020-11-06